

**CRITERIA FOR PRIOR AUTHORIZATION**

## Long-Acting Hemophilia Factors

**PROVIDER GROUP** Pharmacy  
Professional

**MANUAL GUIDELINES** All dosage forms of the following medications will require prior authorization:  
 Adynovate (antihemophilic factor VIII recombinant, PEGylated)  
 Alprolix (coagulation factor IX recombinant, Fc fusion protein)  
 Eloctate (antihemophilic factor VIII recombinant, Fc fusion protein)  
 Esperoct (antihemophilic factor VIII recombinant, PEGylated)  
 Idelvion (coagulation factor IX recombinant, albumin fusion protein (rIX-FP))  
 Jivi (antihemophilic factor VIII recombinant, PEGylated)  
 Rebinyn (coagulation factor IX recombinant, glycol-PEGylated)

**CRITERIA FOR ADYNOVATE** (must meet all of the following):

- Patient must have a diagnosis of hemophilia A (congenital factor VIII deficiency)
- Must meet one of the following:
  - Routine prophylaxis to reduce the frequency of bleeding episodes (must meet all of the following):
    - Frequency of dosing must not be more frequent than twice weekly
    - Dose must not exceed 50 IU/kg for patients 12 years of age and older, or 70 IU/kg for children less than 12 years of age
    - Exceptions will be made when the provider submits documentation of pharmacokinetic assay testing to indicate that the patient requires more frequent or higher dosing
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

**CRITERIA FOR ALPROLIX** (must meet all of the following):

- Patient must have a diagnosis of hemophilia B
- Must meet one of the following:
  - Routine prophylaxis to reduce the frequency of bleeding episodes (must meet all of the following):
    - Dose must not exceed 50 IU/kg once weekly or 100 IU/kg once every 10 days
    - Exceptions will be made when the provider submits documentation of pharmacokinetic assay testing to indicate that the patient requires more frequent or higher dosing
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

**CRITERIA FOR ELOCTATE** (must meet all of the following):

- Patient must have a diagnosis of hemophilia A (congenital factor VIII deficiency)
- Must meet one of the following:
  - Routine prophylaxis to reduce the frequency of bleeding episodes (must meet all of the following):
    - Frequency of dosing must not be more frequent than every 3 days
    - Dose must not exceed 65 IU/kg for patients 6 years of age and older, or 80 IU/kg for children less than 6 years of age
    - Exceptions will be made when the provider submits documentation of pharmacokinetic assay testing to indicate that the patient requires more frequent or higher dosing
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

APPROVED PA Criteria

**CRITERIA FOR ESPEROCT** (must meet all of the following):

- Patient must have a diagnosis of hemophilia A (congenital factor VIII deficiency)
- Must meet one of the following:
  - Routine prophylaxis to reduce the frequency of bleeding episodes (must meet all of the following):
    - Frequency of dosing must not be more frequent than every 4 days
    - Dose must not exceed 65 IU/kg twice weekly for patients less than 12 years of age, or 50 IU/kg every 4 days for patients aged 12 years and older
    - Exceptions will be made when the provider submits documentation of pharmacokinetic assay testing to indicate that the patient requires more frequent or higher dosing
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

**CRITERIA FOR IDELVION** (must meet all of the following):

- Patient must have a diagnosis of hemophilia B
- Must meet one of the following:
  - Routine prophylaxis to reduce the frequency of bleeding episodes (must meet all of the following):
    - Dose must not exceed either 40 IU/kg once every 7 days or 75 IU/kg once every 14 days for patients 12 years of age and older OR 55 IU/kg once every 7 days for children less than 12 years of age
    - Exceptions will be made when the provider submits documentation of pharmacokinetic assay testing to indicate that the patient requires more frequent or higher dosing
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

**CRITERIA FOR JIVI** (must meet all of the following):

- Patient must have a diagnosis of hemophilia A (congenital factor VIII deficiency)
- Patient must have received other treatment for hemophilia A prior to starting treatment with Jivi
- Patient must be 12 years of age or older
- Must meet one of the following:
  - Routine prophylaxis to reduce the frequency of bleeding episodes (must meet all of the following):
    - Frequency of dosing must not be more frequent than twice weekly
    - Dose must not exceed 6000 IU per infusion
    - Exceptions will be made when the provider submits documentation of pharmacokinetic assay testing to indicate that the patient requires more frequent or higher dosing
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

**CRITERIA FOR REBINYN** (must meet all of the following):

- Patient must have a diagnosis of hemophilia B
- Must meet one of the following:
  - On-demand treatment and control of bleeding episodes
  - Perioperative management

**LENGTH OF APPROVAL:** 12 months for prophylaxis (initial and renewal)  
3 months for treatment (per bleed episode)  
1 month for perioperative (per procedure)

---

DRUG UTILIZATION REVIEW COMMITTEE CHAIR

---

DATE

---

PHARMACY PROGRAM MANAGER  
DIVISION OF HEALTH CARE FINANCE  
KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT

---

DATE